Ranked API manufacturers
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for carfilzomib, filing since 2016. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
13 markets
02 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
26 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Last FDA inspection
2025 · NAI
GMP recognised in
23 markets
04 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2016. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Last FDA inspection
2025 · NAI
GMP recognised in
26 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 7 markets.
Last FDA inspection
2025 · NAI
GMP recognised in
7 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2023. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
6 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2017. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Last FDA inspection
2024 · NAI
GMP recognised in
2 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Last FDA inspection
2025 · NAI
GMP recognised in
1 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2025. Its 2024 FDA inspection closed as NAI.
Last FDA inspection
2024 · NAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2024. Its GMP is recognised in 5 markets.
Last FDA inspection
Not established
GMP recognised in
5 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2025. Its 2024 FDA inspection closed as NAI.
Last FDA inspection
2024 · NAI
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2025. Its GMP is recognised in 4 markets.
Last FDA inspection
Not established
GMP recognised in
4 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2025. Its 2025 FDA inspection closed as VAI.
Last FDA inspection
2025 · VAI
GMP recognised in
Not established
14 United States
Makes the API
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2016. Its GMP is recognised in 2 markets.
Last FDA inspection
Not established
GMP recognised in
2 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2023. Its GMP is recognised in 1 market.
Last FDA inspection
Not established
GMP recognised in
1 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for carfilzomib, filing since 2025.
Last FDA inspection
Not established
GMP recognised in
Not established
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for carfilzomib, filing since 2025.
Last FDA inspection
Not established
GMP recognised in
Not established
18 United States
Makes the API
Registered with SFDA (Saudi Arabia) for carfilzomib.
Last FDA inspection
Not established
GMP recognised in
Not established
How this listing is sourced Regulator filings, warehouse snapshot 9 July 2026
View profile 19 Switzerland
Makes the API
Registered with SFDA (Saudi Arabia) for carfilzomib.
Last FDA inspection
Not established
GMP recognised in
Not established
How this listing is sourced Regulator filings, warehouse snapshot 9 July 2026
View profile 17 more manufacturers hold filings for carfilzomib
The names are listed below. The filings, inspection history and GMP certificates behind
each one are available with a free account.
Open the full list with a free account Contract manufacturers (3)
Contract manufacturers make to order rather than holding their own filing for this
molecule.
Finished-dose makers (17)
How this list is built
The order is set by active filings weighted by regulator, inspection outcomes and their
recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags.
Every factor appears on the card it produced.
Read the full method.
- Active US DMFs
- FDA, List of Drug Master Files
- Valid CEPs
- EDQM certificate database
- Inspection outcomes
- FDA inspection classifications
- GMP certificates
- EudraGMDP and national regulators